• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Broadly neutralizing antibody treatment does not prevent overall HIV-1 acquisition

byAvneesh BhanguandHarsh Shah
March 23, 2021
in Chronic Disease, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Broadly neutralizing antibody treatment was shown not to prevent overall HIV-1 acquisition compared to placebo.

2. Sub-group analysis demonstrated broadly neutralizing antibodies could prevent acquisition in HIV-1 isolates.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Though risk reduction measures have helped blunt the spread of human immunodeficiency virus (HIV), preventive treatments can help increase the effectiveness of prevention. VRC01 is an immunoglobulin G-1 (IgG1) broadly neutralizing antibody (bnAb) directed at HIV type 1 (HIV-1). This study determined whether VRC01 was capable of preventing HIV-1 infection. VRC01 provided to at-risk cis-gendered men and trans-gendered persons in the Americas and Europe, and at-risk women in sub-Saharan Africa did not prevent overall HIV-1 acquisition compared to placebo. In prespecified analyses pooling data across trials, the incidence of infection with VRC01 sensitive isolates was lower amongst VRC01 recipients compared to placebo. Study limitations include the lack of reporting on long-term outcomes after treatment with bnAb. Nonetheless, this study’s results are significant as a proof-of-concept trial. Despite showing bnAb did not prevent HIV-1 acquisition, it did show that bnAb could be used against susceptible HIV-1 isolates.

Click to read the study in NEJM

Relevant Reading: Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants

RELATED REPORTS

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

Safety of investigational vaccines against human immunodeficiency virus

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

In-Depth [randomized controlled trial]: This study reported the results on two parallel phase 2b, randomized, proof-of-concept efficacy trials of bnAb VRC01 in at-risk cis-gendered men and trans-gendered persons in the Americas and Europe, and at-risk women in sub-Saharan Africa. 2,699 participants (HVTN 704/HPTN 085 trial) and 1,924 participants (HVTN 703/HPTN 081 trial) were enrolled in the study and randomized in a 1:1:1 ratio to either low dose VRC01 (10 mg/kg), high dose VRC01 (30 mg/kg) or placebo treatment, respectively. The study’s primary endpoint was documental HIV-1 infection by the week 8 trial visit. In HVTN 704/HPTN 085, the overall estimated prevention efficacy was 22.4% compared to placebo at the week 80 visit in the low dose group (95% confidence interval [CI], −25.5 to 52.0), 30.9% (95% CI, −13.9 to 58.0) in the high dose group, and 26.6% (95% CI, −11.7 to 51.8; P = 0.15) in the pooled VRC01 group. In HVTN 703/HPTN 081, the overall estimated prevention efficacy was –9.3% (95% CI, −85.3 to 35.5) in the low-dose group, 27.0% (95% CI, −30.7 to 59.3) in the high-dose group, and 8.8% (95% CI, −45.1 to 42.6; P = 0.70) in the pooled VRC01 group. In assessing the association between protection at week 80 and viral strain sensitivity, an analysis of pooled data from the two trials showed the incidence of infection with sensitive viruses was 0.20 per 100-person years amongst VRC01 recipients compared to 0.86 per 100-person years in placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). Overall, this study demonstrated bnAb did not prevent overall HIV-1 acquisition but did show proof of concept efficacy in bnAb sensitive HIV-1 isolates.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: broadly neutralizing antibodyhuman immunodeficiency virus (HIV)immunoglobulin
Previous Post

Association of co-exposure of antenatal steroid and prophylactic Indomethacin with spontaneous intestinal perforation

Next Post

Total knee replacement cost-effective in obese patients with knee osteoarthritis

RelatedReports

Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons
StudyGraphics

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

December 11, 2024
Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is  Non-inferior to Donors Without HIV
StudyGraphics

Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is Non-inferior to Donors Without HIV

October 24, 2024
Next Post
Total knee replacement with post-surgical regimen yields greater relief vs nonsurgical treatment alone

Total knee replacement cost-effective in obese patients with knee osteoarthritis

Bilateral diagonal earlobe creases associated with increased risk of coronary artery disease

Trends in hearing loss prevalence and years lived with disability worldwide from 1990-2019

#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval

#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.